T lymphocyte activation through stimulation of the T cell receptor complex and co-stimulatory receptors is associated with acute tyrosine phosphorylation of intracellular proteins, which in turn mediate downstream signaling events that regulate interleukin-2 expression and cell proliferation. The extent of protein tyrosine phosphorylation is rapidly attenuated after only 1-2 min of stimulation as a means of tightly controlling the initial signaling response. Here we show that this attenuation of tyrosine phosphorylation of Shc, CrkL, and the proto-oncogene Cbl is mimicked by treatment of mouse T lymphocytes or cultured Jurkat cells with phorbol 12-myristate 13-acetate. This effect is blocked by the specific protein kinase C inhibitor GF109203X, but not by PD98059, an inhibitor of MEK1/2 kinase. Activation of protein kinase C by phorbol ester also causes rapid (t1 ⁄2 ‫؍‬ 2 min) dissociation of both CrkL and p85/phosphoinositide 3-kinase from Cbl concomitant with Cbl tyrosine dephosphorylation. More important, GF109203X treatment of Jurkat cells prior to T cell receptor stimulation by anti-CD3/CD4 antibodies results in an enhanced (2-fold) peak of Cbl phosphorylation compared with that observed in control cells. Furthermore, the rate of attenuation of both Cbl tyrosine phosphorylation and its association with CrkL following stimulation with anti-CD3/CD4 antibodies is much slower in Jurkat cells treated with GF109203X. Taken together, these data provide strong evidence that one or more isoforms of phorbol ester-responsive protein kinase C play a key role in a feedback mechanism that attenuates tyrosine phosphorylation of proteins and reverses formation of signaling complexes in response to T cell receptor activation.
T lymphocyte activation through stimulation of the T cell receptor complex and co-stimulatory receptors is associated with acute tyrosine phosphorylation of intracellular proteins, which in turn mediate downstream signaling events that regulate interleukin-2 expression and cell proliferation. The extent of protein tyrosine phosphorylation is rapidly attenuated after only 1-2 min of stimulation as a means of tightly controlling the initial signaling response. Here we show that this attenuation of tyrosine phosphorylation of Shc, CrkL, and the proto-oncogene Cbl is mimicked by treatment of mouse T lymphocytes or cultured Jurkat cells with phorbol 12-myristate 13-acetate. This effect is blocked by the specific protein kinase C inhibitor GF109203X, but not by PD98059, an inhibitor of MEK1/2 kinase. Activation of protein kinase C by phorbol ester also causes rapid (t1 ⁄2 ‫؍‬ 2 min) dissociation of both CrkL and p85/phosphoinositide 3-kinase from Cbl concomitant with Cbl tyrosine dephosphorylation. More important, GF109203X treatment of Jurkat cells prior to T cell receptor stimulation by anti-CD3/CD4 antibodies results in an enhanced (2-fold) peak of Cbl phosphorylation compared with that observed in control cells. Furthermore, the rate of attenuation of both Cbl tyrosine phosphorylation and its association with CrkL following stimulation with anti-CD3/CD4 antibodies is much slower in Jurkat cells treated with GF109203X. Taken together, these data provide strong evidence that one or more isoforms of phorbol ester-responsive protein kinase C play a key role in a feedback mechanism that attenuates tyrosine phosphorylation of proteins and reverses formation of signaling complexes in response to T cell receptor activation.
T cell receptor (TCR)
1 ligation by antigen-presenting cells or by antibodies to the CD3-TCR complex causes rapid increases in the activities of protein-tyrosine kinases and in the tyrosine phosphorylation of cellular substrates. The kinases involved belong to two families of nonreceptor protein-tyrosine kinases, the Src (Fyn and Lck) and Syk (Syk and ZAP-70) families (1) (2) (3) . Activation of Lck and/or Fyn leads to the tyrosine phosphorylation of immunoreceptor tyrosine-based activation motifs present in the intracellular segments of the CD3 ⑀-and -proteins (4, 5), followed by the recruitment, tyrosine phosphorylation, and activation of ZAP-70. This biochemical response couples the TCR to a diverse group of signal transduction molecules, including adaptor proteins, serine/threonine kinases, phospholipids and their cleavage products, and GTP-binding proteins, leading ultimately to interleukin-2 production and cell proliferation. Such proliferation of T lymphocytes directed against a specific antigen is crucial to mounting appropriate cell-based immune responses to foreign entities.
The increased tyrosine phosphorylation of cellular proteins observed after TCR activation is a transient process, apparently a result of the combined actions of protein-tyrosine kinases and phosphatases. The ensuing desensitization of tyrosine kinase signaling after stimulation is likely to be important in coordinating the complex network of events that lead to T cell proliferation. An integral part of this response is an internalization of the TCR complex, followed by its degradation by a mechanism that involves the targeting of the internalized receptors to an endocytic degradative pathway (6, 7). However, the maximal level of protein tyrosine phosphorylation in response to TCR stimulation occurs after only 1 or 2 min, and the decrease in tyrosine phosphorylation of cell proteins is rapid following this peak (8) . The rapid kinetics of protein tyrosine dephosphorylation indicate that T cell receptor internalization cannot fully account for deactivation of the signaling pathways following T cell stimulation, but other mechanisms that may be involved are unknown.
Two cellular protein substrates for T cell receptor-activated tyrosine kinases that undergo rapid phosphorylation and dephosphorylation in response to antigen presentation are the proto-oncogene products c-Cbl and CrkL. Both have prominent roles in T cell signaling, serving to link receptor tyrosine kinases to downstream effectors such as p85/PI 3-kinase (9 -11). CrkL, the cellular homologue of the v-crk oncogene product (12) , consists of one SH2 and two C-terminal SH3 domains (13, 14) . The SH3 domain of CrkL binds to several proteins, including C3G, Sos, and c-Abl (15, 16) . Cbl is the cellular homologue of v-Cbl, an oncogene that causes lymphomas in murine B cells (17, 18) . Cbl contains an amino-terminal phosphotyrosinebinding domain (19) , a Ring finger domain, and a carboxylterminal leucine zipper domain. Cbl also possesses a number of proline-rich motifs as well as several tyrosine residues in the C terminus that serve as binding sites for SH3 and SH2 domains, respectively (18) . In T lymphocytes, TCR ligation results in the association of a large pool of CrkL and Cbl through either the SH2 or SH3 domain of CrkL or both (20 -24) .
Genetic and biochemical studies have generally supported the concept that Cbl functions as a negative regulator of receptor tyrosine kinase signaling (25) (26) (27) (28) . Overexpression of c-Cbl in mast cells suppresses Syk kinase activity (27) and impairs Ras-dependent AP1 activation after TCR ligation in Jurkat cells (29) . We reported that D-Cbl, the Drosophila homologue of Cbl containing only the N-terminal portion of the protein, acts as a negative regulator of receptor tyrosine kinase-mediated R7 photoreceptor cell development in Drosophila (26) . The use of c-Cbl-deficient mice has provided further evidence that c-Cbl is involved in the negative control of T cell function. The c-Cbldeficient mice display marked changes in their hemopoietic profiles, including an enhanced selection of CD4 ϩ T cells, altered TCR expression, lymphoid hyperplasia, primary splenic extramedullary hemopoiesis, and increased ZAP-70 activity (30, 31) . Interestingly, the tyrosine phosphorylation of Cbl and its association with p85/p110 PI 3-kinase indicate that the protein also plays some positive signaling role in T cell function. This is reinforced by recent experiments on interleukin-4 signaling (32) and the fact that T cell activation is wortmanninsensitive (33) .
One possible mechanism for the attenuation of tyrosinephosphorylated receptors and substrate proteins that occurs following initial tyrosine phosphorylation in response to TCR stimulation is suggested by recent data on the serine/threonine phosphorylation of these proteins. For example, substantial evidence suggests that rapid serine/threonine phosphorylation of the insulin receptor and its substrate IRS-1 correlates with their decreased tyrosine phosphorylation and decreased binding of IRS-1 to p85/p110 PI 3-kinase (34, 35) . The serine/ threonine phosphorylation of IRS-1 causes its binding to 14-3-3 proteins, which may block further tyrosine phosphorylation (36) . It has been shown recently that after TCR stimulation, Cbl is phosphorylated not only on tyrosine, but also on serine, and that this post-translational modification regulates its interaction with 14-3-3 -proteins (37, 38) . The phorbol ester PMA was also able to cause serine phosphorylation of Cbl and to induce its interaction with 14-3-3 -proteins, implicating the protein kinase C family of serine/threonine kinases in Cbl function. These considerations prompted us to test whether protein kinase C isoforms might be involved in mediating the attenuation of Cbl tyrosine phosphorylation in T lymphocytes following T cell receptor activation. We show here that activation of protein kinase C by phorbol ester causes rapid dephosphorylation of tyrosine phosphate sites on three protein substrates of T cell tyrosine kinases (Shc, CrkL, and Cbl) and that the protein kinase C inhibitor GF109203X causes hyperphosphorylation of Cbl in response to T cell receptor engagement. These results support a key role of protein kinase C in signal attenuation during T lymphocyte stimulation.
MATERIALS AND METHODS
Antibodies and Reagents-Cbl was immunoprecipitated with polyclonal antibody prepared against the N terminus of Cbl (9) and blotted with polyclonal Cbl (Santa Cruz Inc.). Rabbit polyclonal anti-CrkL and anti-C3G antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); mouse anti-CD3 antibody 145-2C11 was from Pharmingen; and monoclonal anti-phosphotyrosine antibody 4G10 and polyclonal anti-PI 3-kinase (p85) antibody were from Upstate Biotechnology, Inc. (Lake Placid, NY). The polyclonal anti-Shc antibody was obtained from Transduction Laboratories (Lexington, KY). The polyclonal anti-phospho-MAPK antibody was a gift of Dr. Mario Stevenson. The monoclonal anti-CD3 (OKT3) and anti-CD4 (OKT4) antibodies were purified from cell culture supernatants as described previously (9) . PMA was purchased from Sigma. The inhibitors bisindolylmaleimide I (GF109203X), PD98059, and SB203580 were from Calbiochem.
Cell Culture and Activation-The Jurkat cell line E6.1 obtained from the American Type Culture Collection was grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 10 mM HEPES (pH 7.4), 50 M 2-mercaptoethanol, and penicillin/streptomycin. SV40 T antigen-transfected human leukemic Jurkat T cells (Jurkat-TAg) were kindly supplied by Dr. Hamid Band and cultured as indicated above. Similar results were obtained with both cell types. Murine T lymphocytes were prepared by removing spleens of C57BL/6 mice, and the cells were passed over an IgG column (Pierce) to remove B lymphocytes and resuspended in serum-free RPMI 1640 medium. Fluorescence-activated cell sorter analysis with B220 ϩ antibody as a B cell marker showed that the purified cells were Ͼ85% CD4 ϩ CD8 ϩ T lymphocytes.
Preparation of Cell Lysates, Immunoprecipitation, and Immunoblotting-Cells were washed twice in RPMI 1640 medium without serum and antibiotics and stimulated in the same medium. Cells were activated either by cross-linking the CD3 and CD4 receptors (9) or by adding PMA (50 ng/ml), followed by incubation at 37°C for different times. After stimulation, cells were washed immediately in cold phosphate-buffered saline containing 0.5 mM Na 3 VO 4 , 5 mM EDTA, and 10 mM NaF and lysed with 1% Nonidet P-40 in buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM vanadate, 0.1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 25 g/ml aprotinin for 10 min on ice. Nuclei were removed by centrifugation at 12,000 ϫ g for 2 min. Protein concentrations were determined by the Bradford assay (Bio-Rad). Antibodies were mixed with clarified lysates containing 0.3-0.5 mg of protein and incubated overnight at 4°C. Protein A-Sepharose (Sigma) was added for the last 2 h, and at the end of this period of time, beads were washed twice in 0.2% Nonidet P-40 buffer and once in 0.2% Nonidet P-40 buffer containing 0.5 M NaCl. Proteins were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted. Immunodetection was performed by chemiluminescence (Roche Molecular Biochemicals).
RESULTS

PMA Decreases the Tyrosine Phosphorylation of Cbl and p52
Shc -To test whether protein kinase C activation modulates the tyrosine phosphate content of lymphocyte proteins, Jurkat cells were incubated with or without PMA or OKT3 plus OKT4 prior to preparation of cell lysates, SDS-PAGE, and Western blotting with anti-phosphotyrosine antibody. As shown in Fig.  1A , the tyrosine phosphorylation state of several proteins was differentially affected by treatment of Jurkat cells for 15 min at 37°C with 50 ng/ml PMA or by TCR cross-linking with OKT3 plus OKT4 and activation for 2 min. In particular, the tyrosine phosphorylation of several proteins (pp1-pp4) appearing at 110, 61, 54, and 52 kDa was modified by PMA. The protein migrating at 110 kDa was likely to be Cbl, and pp4 could represent the p52 isoform of Shc. To characterize the identity of these proteins, we immunoprecipitated lysates from PMA-and OKT3 plus OKT4-stimulated cells with anti-Cbl (Fig. 1B) or anti-Shc (Fig. 1C) antibodies. Immunoblotting with anti-phosphotyrosine antibody (4G10) revealed that in contrast to TCR stimulation, PMA treatment decreased the tyrosine phosphorylation content of Cbl (Fig. 1B) . Similarly, Fig. 1C shows that the band corresponding to pp4 is likely to be the p52 isoform of Shc and that addition of PMA results in a decrease in the p52
Shc tyrosine phosphorylation state. The identity of the pp3 protein in lane 2 is Lck (data not shown), which has been reported to be converted to a form with slower mobility after PMA stimulation (39 -41) .
PMA Stimulation Reduces the Association of Cbl with CrkL and p85-Several groups have reported that CrkII and CrkL become tyrosine-phosphorylated in response to growth factors such as erythropoietin, interferon, epidermal growth factor, insulin-like growth factor 1, or insulin and associate with Cbl (24, (42) (43) (44) . CrkI and CrkII have been also reported to interact with Cbl, although to a lesser extent than CrkL (22) . We examined the role of protein kinase C in modulating these interactions by immunoprecipitating CrkL from Jurkat cells stimulated either by cross-linking the TCR or with PMA and analyzing the immunoprecipitates for the presence of Cbl and the p85 regulatory subunit of PI 3-kinase. Fig. 2A shows that TCR stimulation increased and PMA decreased CrkL tyrosine phosphorylation. Blotting of the CrkL immunoprecipitates with anti-Cbl showed that this correlated with a decrease in Cbl binding to immunoprecipitated CrkL. Pretreatment of Jurkat cells with PMA for 5 min at 37°C, followed by activation with OKT3 plus OKT4 (Fig. 2B) , reduced the tyrosine phospho-rylation of CrkL by 50% compared with cells treated with OKT3 plus OKT4 alone.
A prominent feature of TCR activation is the transient association of p85 with CrkL and Cbl (9, 21, 22) . Fig. 2A shows that the association of p85 with CrkL was increased by TCR stimulation (fourth panel, lane 3 versus 4) and that this interaction was reduced by PMA treatment (lane 2 versus 1) . When Jurkat cell lysates were immunoprecipitated with anti-Cbl antibody (Fig. 2C) and blotted with anti-CrkL or anti-p85 antibody, we observed that PMA decreased and OKT3 plus OKT4 increased the association of CrkL and p85 with immunoprecipitated Cbl, confirming the results obtained using anti-CrkL immunoprecipitates.
We next tested whether the PMA-mediated dissociation of CrkL and Cbl observed in Jurkat cells is also observed in lymphocytes isolated from lymph nodes and spleens of C57BL/6 mice (Fig. 2D) . The basal level of Cbl-CrkL binding in CrkL immunoprecipitates (lane 2) was increased by a 2-min incubation with anti-CD3 antibody and completely blocked in lymphocytes treated with PMA for 15 min (lane 3). The data therefore show that in primary mouse T cells or in the Jurkat cell line, PMA induces a rapid dissociation of Cbl from p85 and CrkL.
The Association between CrkL and p85 Is Mediated through Cbl-Although p85 clearly binds directly to Cbl (45) (46) (47) , and the mutation Y731F blocks this association (32, 48) , 2 it is not clear whether the CrkL-p85 association shown in Fig. 2 is direct or is mediated by Cbl (23, 49) . We have shown (Fig. 2 ) that p85 binding to complexes containing CrkL and Cbl was ϩ CD8 ϩ T lymphocytes from C57BL/6 mice were activated with PMA (50 ng/ml, 5 min, 37°C) or anti-CD3 antibody (10 g/ml, 2 min, 37°C), and CrkL was immunoprecipitated from 200 g of cell lysate and subjected to SDS-PAGE and transferred to nitrocellulose (lanes 2-4) . The nitrocellulose membrane was immunoblotted with anti-Cbl and anti-CrkL antibodies and visualized by chemiluminescence. enhanced by T cell receptor cross-linking, suggesting an SH2-phosphotyrosine interaction, yet no YMXM motif that binds the SH2 domain of p85 (50) is present in CrkL. We have addressed this issue by immunodepleting Cbl from lysates of T lymphocytes, followed by blotting the subsequent anti-CrkL immunoprecipitates with anti-p85 antibody (Fig. 3) . The results show that both antibodies (anti-Cbl and anti-CrkL) immunoprecipitated p85 (Fig. 3, lanes 1-4 and 12-15 ), but in lysates that had been immunodepleted of Cbl (lanes 6 -9), p85 bound to CrkL could no longer be detected. Anti-phosphotyrosine blots (Fig. 3 , fourth panel) confirmed that tyrosine-phosphorylated Cbl was no longer associated with CrkL in lysates immunodepleted of Cbl (lanes 6 -9) . The lower amount of immunoprecipitated CrkL in lysates immunodepleted of Cbl compared with control lysates is probably due to the loss of Cbl-CrkL complexes during the Cbl preclearing (second panel, compare lanes 1-4 and 6 -9). Finally, it should be noted that the pool of Cbl bound to CrkL was highly tyrosine-phosphorylated compared with the total Cbl pool (lane 4 versus 15). These results support the concept that a large fraction of p85 is present in complexes with CrkL because both proteins are directly associated with tyrosine-phosphorylated Cbl.
The PMA-mediated Decrease in Tyrosine-phosphorylated Cbl Is Dependent on Protein Kinase C and Independent of MEK1/2 and p38 MAPKs-In T cells, PMA activates protein kinase C, Ras, and Raf-1 kinases, resulting in the activation of MEK and extracellular receptor kinase kinases (51, 52) . To test whether the decrease we observed in Cbl and CrkL tyrosine phosphorylation by PMA treatment is mediated by the protein kinase C pathway, we pretreated T lymphocytes with GF109203X (a specific inhibitor of conventional and novel protein kinase C isoforms) (53) or PD98059 (a MEK1/2 inhibitor) (54, 55) before PMA stimulation. We also employed the inhibitor SB203580, known to specifically block the p38 MAPK pathway (56) , which is weakly activated by PMA treatment (57) . Lysates of PMAtreated cells were then immunoprecipitated with anti-CrkL antibody and blotted with anti-Cbl, anti-p85, or 4G10 antibodies. Fig. 4 shows that PMA treatment caused dissociation of Cbl from CrkL (lane 1 versus 2), and this was prevented by GF109203X (lane 4), but not by the specific inhibitor of MAPK kinase or p38 (lanes 7 and 9) . Blotting with anti-p85 antibody showed that the dissociation of p85 from signaling complexes was blocked only by the protein kinase C inhibitor (lane 4). Fig.  4 (panel B) shows that GF109203X and PD98059 prevented MAPK activation and that SB203580 was ineffective. Therefore, the Cbl-CrkL dissociation induced by PMA treatment appears to be dependent on protein kinase C and occurs by a mechanism upstream of MEK activity.
Enhanced OKT3/OKT4-stimulated Tyrosine Phosphorylation of Cbl in Cells Treated with Protein Kinase C Inhibitor-
The specific effect of the protein kinase C inhibitor GF109203X to maintain the tyrosine-phosphorylated state of Cbl suggests that PMA acts through protein kinase C activation. To test whether protein kinase C activation in response to T cell receptor cross-linking represses tyrosine phosphorylation that occurs upon T cell stimulation, the kinetics of tyrosine phosphorylation of Cbl and its attenuation were measured in Jurkat cells treated or not with GF109203X and then stimulated with OKT3 and OKT4 for several periods of time. After these treatments, Jurkat cells were lysed, and the lysates were immunoprecipitated with anti-CrkL antibody. As shown in Fig. 5A and by others (22) , ligation of the CD3 and CD4 co-receptors resulted in a rapid association of tyrosine-phosphorylated Cbl with CrkL, followed by equally rapid dissociation of these complexes (t1 ⁄2 ϭ 2 min) (Fig. 5B) . Interestingly, after only 5 min of stimulation of Jurkat cells with OKT3 plus OKT4 (Fig. 5A, lane  4) , complexes containing Cbl and CrkL were actually lower in abundance than in cells that were never stimulated. Thus, attenuation of Cbl tyrosine phosphorylation and its dissociation from CrkL following T cell receptor ligation is not simply a mechanism that returns this system to a previous steady state, but rather drives it to a lower level of tyrosine phosphorylation. In Jurkat cells treated with GF109203X, the increase in tyrosine phosphorylation of CrkL-associated Cbl in response to a 2-min treatment with OKT3 plus OKT4 was found to be markedly elevated compared with control cells (lanes 6 -8) . Strikingly, return to basal values for these parameters was prolonged from Ͻ5 min after OKT3 plus OKT4 addition in control cells to ϳ20 min in GF109203X-treated Jurkat cells (cf. lanes 4  and 8) . These data indicate that inhibition of protein kinase C in Jurkat cells is associated with marked potentiation of T cell (lanes 1-10) , anti-Cbl antibody ( lanes  12-15) , or normal serum (NS; lanes 5, 11, and 16 ). In lanes 6 -10, lysates were first immunoprecipitated (Pre IP) with anti-Cbl antibody (lanes 6 -9) or normal serum (lane 10), and the supernatants were then reacted with anti-CrkL antibody. The immunoprecipitates were subjected to 10% SDS-PAGE and then probed successively with anti-p85, anti-CrkL, anti-Cbl, and 4G10 antibodies and visualized by chemiluminescence.
FIG. 4. Dissociation of the binding of CrkL to
Cbl by PMA is dependent on protein kinase C and independent of MEK1/2 or p38 MAPK activities. Jurkat E6.1 cells were treated or not on ice for 15 min with GF109203X (2.5 M), SB203580 (5 M), or PD98059 (50 M) and then stimulated with PMA (50 ng/ml, 15 min, 37°C). A, lysates were prepared, immunoprecipitated (IP) with anti-CrkL antibody, and subjected to SDS-PAGE. The immunoblot was serially probed with anti-Cbl, anti-p85, anti-CrkL, and anti-phosphotyrosine (4G10) antibodies and visualized by chemiluminescence. B, total cell lysates (10 g) were resolved by 10% SDS-PAGE and visualized with specific antiphospho-MAPK antibodies. NS, normal serum.
receptor signaling at the level of substrate tyrosine phosphorylation as well as delayed attenuation of this response.
Based on the data in Fig. 5 showing a rapid attenuation of Cbl-CrkL association following T cell receptor ligation, we tested whether activation of protein kinase C by PMA in Jurkat cells in the absence of T cell activation results in a comparable time course of Cbl-CrkL complex dissociation. In these experiments, lysates of Jurkat cells treated with or without PMA for various times were immunoprecipitated with anti-CrkL antibody, followed by immunoblot analysis using anti-Cbl antibody. Fig. 6 shows that the time course of Cbl-CrkL complex dissociation in response to PMA was rapid, with t1 ⁄2 ϭ 2 min. This similar rapid decline in the abundance of Cbl-CrkL complexes after PMA treatment versus that which follows the peak response to T cell receptor ligation is consistent with a role of protein kinase C in mediating at least part of T cell receptor attenuation.
DISCUSSION
The data presented here show that PMA addition to T cells causes a rapid decline in the tyrosine phosphorylation state of Shc, CrkL, and Cbl (Fig. 1) . This effect coincides with rapid dissociation of Cbl-CrkL protein complexes (Fig. 2) . More important, the time course of this dissociation is similar to that observed following the transient formation of Cbl-CrkL complexes in response to TCR/CD3 receptor stimulation (Fig. 6) . Conversely, when protein kinase C activity is blocked by the inhibitor GF109203X, tyrosine phosphorylation of Cbl and CrkL following TCR/CD3 ligation is significantly amplified (Fig. 5) . These results suggest that activation of protein kinase C following TCR ligation, thought to initiate downstream signaling events, also leads to a feedback mechanism that reduces tyrosine phosphorylation of Cbl and CrkL and hence return to the non-activated state. The PMA-induced dephosphorylation of Shc and other proteins (Fig. 1) and its prevention by GF109203X indicate that protein kinase C activation modulates the tyrosine phosphorylation state of other cellular proteins besides Cbl and CrkL.
It is well established that both phorbol esters and TCR ligation by antigen-presenting cells or by anti-CD3 antibody induce internalization of the TCR. The half-life of the TCR complex on the cell surface after PMA treatment is ϳ10 min (58 -60) . The TCR is not degraded, but is recycled in a functional state back to the cell membrane (61, 62) . In contrast to PMA-induced down-regulation and recycling, TCR ligation by antigen-presenting cells or anti-CD3 antibody results in an internalization and targeting to lysosomes for degradation (63, 64) . The t1 ⁄2 of ligand-induced TCR degradation has been shown by various investigators to be 15-30 min (6, 7, (63) (64) (65) (66) . By contrast, the data presented here show that the Cbl-CrkL complex is dissociated by PMA or OKT3 plus OKT4 (Figs. 1 and 6 ) significantly faster, with a t1 ⁄2 of 2 min. Therefore, the dissociation of CrkL and Cbl precedes, and is not simply a consequence of, activation-induced TCR endocytosis. The similar kinetics of Cbl-CrkL dissociation by TCR ligation or by PMA and blockade of this dissociation by GF109203X are evidence that protein kinase C activation is involved.
We also report here that PMA causes the dissociation of CrkL from the p85 subunit of PI 3-kinase (Fig. 2) and that Cbl mediates the association of p85 with CrkL (Fig. 3) . These findings are consistent with results obtained in c-Fms Chinese hamster ovary cells activated by colony-stimulating factor-1, in which prior removal of Cbl from cell lysates diminished by 95% the amount of PI 3-kinase associated with CrkII (67). By contrast, in MO7e cells, CrkL appears to bind directly to p85 through the CrkL SH3 domains, and this interaction is further increased by Steel factor (23) . The reason for these discrepancies is unknown and can reflect differences in the mechanisms of Cbl-CrkL association in different cell types. Although CrkL becomes tyrosine-phosphorylated upon T cell activation, no consensus motif is present for the binding of the SH2 domain of p85 (49) . These data suggest that Cbl may play a role as a multifunctional adaptor protein, interacting independently with CrkL and p85, and that PI 3-kinase is dissociated from Cbl after PMA stimulation. It is not known if p85 becomes serine-phosphorylated under the conditions described here; however, it has been demonstrated that serine phosphorylation of the p85 subunit of PI 3-kinase greatly reduces PI 3-kinase activity (68, 69) .
The ability of the highly specific cell-permeable protein kinase C inhibitor GF109203X to block Cbl-CrkL dissociation is strong evidence that the activation of a conventional or novel protein kinase C isoform is required. GF109203X has no effect on the activity of receptor tyrosine kinases such as insulin, epidermal growth factor, and platelet-derived growth factor receptors (53) . Although all protein kinase C isoforms can be activated by phospholipids in various cell types, only protein kinases C␣ and C are rapidly translocated to the cell membrane of T lymphocytes following antigen-presenting cell recognition (70, 71) . Activation of protein kinase C leads, in turn, to an increase in interleukin-2 receptor expression and activation of the MAPK c-Jun N-terminal kinase (70, 72) . Because TCR ligation results in the membrane translocation of Cbl as well (45) , it is possible that protein kinase C binds to and directly phosphorylates Cbl (11) . Evidence that Cbl becomes serine-phosphorylated after PMA or TCR stimulation has been demonstrated by Liu et al. (37, 38) . In these studies, TCR activation caused the serine phosphorylation of a serine-rich region of Cbl extending from amino acids 615 to 644 and enhanced the binding of Cbl to the 14-3-3 protein. However, it is also possible that protein kinase C acts indirectly, i.e. through an activation-dependent decrease in serine phosphatase or increase in tyrosine phosphatase activity. In this context, Cbl was found to be a substrate of the SH2 domain-containing phosphotyrosine phosphatase SHP-1 (73) . It will be important to determine whether the introduction of inactive forms of protein kinase C isozymes, particularly protein kinase C, into T lymphocytes modulates Cbl tyrosine phosphorylation and blocks Cbl-CrkL dissociation.
Reversible tyrosine phosphorylation is a critical mechanism for the regulation of signal transduction, cell growth, differentiation, and development. It is well established that protein kinase C-mediated serine/threonine phosphorylation of growth factor receptors causes an inhibition of receptor protein-tyrosine kinase activity (74) . In human 293 cells, the IRS-1 adaptor protein, which is extensively tyrosine-phosphorylated by the insulin receptor tyrosine kinase after insulin activation, also becomes serine-phosphorylated (75) , which correlates with the decreased binding of IRS-1 to p85 (34) . Activation of endogenous or transfected protein kinase C by PMA causes extensive serine phosphorylation of IRS-1, resulting in an inhibition of IRS-1 tyrosine phosphorylation by insulin (35) and the development of insulin resistance (76) . Similarly, it is well established that TCR ligation causes the tyrosine phosphorylation of phospholipase C-␥1, leading to activation of protein kinase C, which in turn phosphorylates phospholipase C-␥1 on serine residues and reverses tyrosine phosphorylation (77) . Also in T cells, PMA treatment reduces the in vitro and in vivo CD28 tyrosine phosphorylation from anti-CD28 antibody-stimulated cells (78) , resulting in interleukin-2 production. Thus, serine phosphorylation of several signaling proteins coincides with dephosphorylation of these proteins on tyrosine residues, an event that may provide a critical negative feedback signal for the inhibition of growth factor signaling. In a recent work by Finco et al. (79) , it has been show that the mutant Jurkat T cell line JCaM2 is deficient in pp36/LAT expression, resulting in defective TCR-mediated signal transduction. More important, these cells show an elevated tyrosine phosphorylation of Cbl and a significantly diminished phosphorylation of phospholipase C-␥1 and generation of inositol phosphates. It is conceivable that in the absence of LAT, phospholipase C-␥1-dependent activation of protein kinase C does not occur, mimicking the effect of protein kinase C inhibition by GF109203X on Cbl tyrosine phosphorylation. Further work will be required to test this hypothesis.
